Download For New and Renewal Applications (PHS 398) – DO NOT SUBMIT

Principal Investigator/Program Director (Last, first, middle):
For New and Renewal Applications (PHS 398) – DO NOT SUBMIT UNLESS REQUESTED
For Non-competing Progress Reports (PHS 2590) – Submit only Active Support for Key Personnel
Other Support
CAROL MOINPOUR, PH.D.
ACTIVE
5 U10 CA37429 (Coltman)
Cancer Therapy & Research Center
Prostate Cancer Prevention Trial/Long Term Follow Up
06/01/2007 – 05/31/2009
$430637
0.48 cal mos
The Southwest Oncology Group Statistical Center is participating in this 10-year prostate cancer prevention
trial; an 11th year is included for data analysis and manuscript production. Initial enrollment of registered
participants ended in December 1996. About 18,500 randomized participants will be followed for period
prevalence of disease
The Prostate Cancer Prevention Trial was stopped early and the results of the study were published on
June 24, 2003. The study results reported a higher rate of high grade prostate cancer among men who
were taking finasteride. Of the 18,882 men randomized to the PCPT, approximately 2,300 men were
diagnosed with prostate cancer. The primary objective of the LTFU study is to determine the metastatic
prostate cancer risk for men who were diagnosed with prostate cancer on the PCPT. Prostate cancer
treatment data will be collected and men will be followed twice yearly for a diagnosis of metastatic disease
and death.
UW447992 (Ramsey)
CDC
SIP25: Localized Prostate Cancer: Decision Making and
Outcomes
09/30/2005 – 09/29/2008
$86,759
0.36 cal mos
This prospective study of approximately 400 patients with localized prostate cancer, their spouses and
physicians will obtains information about the decision process, and relate this to quality of life and
satisfaction with care following the treatment decision. Pre-treatment surveys of patients, physicians and
spouses will focus on assessments of quality of life, treatment preferences, and factors influencing those
preferences. Post-treatment surveys of the patient and spouse will assess quality of life, satisfaction with
care, and seek to identify factors that were not anticipated or discounted a the time of the treatment
decision that later were influential to patient’s and spouse’s appraisal of quality of life. Survey sites include
large urology practices in San Antonio and Los Angeles.
5 U10 CA38926 (Crowley)
National Institutes of Health/National Cancer Institute
Southwest Oncology Group Statistical Center
04/01/2004 – 12/31/2009
$4,229,824
2.16 cal mos
The Southwest Oncology Group is a national consortium of institutions and investigators organized to
improve survival of cancer patients through clinical research. The Statistical Center staff at Fred
Hutchinson Cancer Research Center (FHCRC) assist with study protocols, manage and edit study data,
generate semiannual reports of findings, and conduct workshops on data management activities. They
also research statistical aspects of Group studies and analyze and publish study results. Several programs
previously funded via the Group Operations Office/Cancer Therapy and Research Center are included
here: Cooperative Group Outreach Program (CGOP), Pathology Central Office, Urologic Cancer Outreach
Program (UCOP), CTEP Minorities Program, High Priority Clinical Trials and Leukemia Biology.
CTRF S0421 (Moinpour)
Cancer Therapy & Research Foundation
SWOG S0421 Phase III Study of Docetaxel and Atrasentan
PHS 398/2590 (Rev. 11/07)
Page _____
08/21/2006 -08/20/2010
$18,241
1.20 cal mos
Other Support Format Page
Principal Investigator/Program Director (Last, first, middle):
vs Docetaxel and Placebo
To provide expertise in Quality of Life studies including QOL form development, data processing,
monitoring of data quality and programming for all related QOL data forms
5 U10 CA 37429 (Coltman)
NIH/NCI/Cancer Therapy & Research Center
CCOP Community Clinical Oncology ProgramCancer
Research And Biostatistics
12/01/2003—11/30/2008
$457,277
4.20 cal mos
R01 CA120933-01A2 (Cherrier)
University of Washington subaward
Assessment of Cognitive and Mood Effects from ADT in
Men with Prostate Cancer
06/01/2007 – 05/31/2009
$29,082
0.60 cal mos
This project will assess the cognitive, emotional and quality of life changes in men with non-metastatic
prostate cancer who are treated on a clinical trial of intermittent androgen suppression (IAS). The study will
also bring the testosterone back to physiological levels at a predictable time after stopping ADT. Use of the
"off-on-off1 design will allow an examination of intra-patient changes. The proposed study will also compare
the ADT treated patients to a prostate cancer control group (non-metastatic) matched for duration since
primary treatment for between group comparisons. Increasing our understanding of the incidence and
nature of cognitive, mood and quality-of-life changes from ADT, may help health care professionals better
recognize and treat mood and cognitive changes from ADT as well as informing patients of what to expect
prior to treatment. A prospective study of psychosocial and cognitive factors of ADT with an appropriate
control group represents a large contribution to the body of knowledge with regard to prostate cancer.
(Moinpour)
University of Washington
Biobehavioral Cancer Prevention and Control Training
Program
07/01/2008 – 06/30/2009
$6,667
0.60 cal mos
Dr. Moinpour will assist in the recruitment, selection and evaluation of trainees for the program and will
continue to mentor her predoctoral students and be available to others as needed.
1R21CA131651-01A2 (Donaldson)
06/01/09-05/31/2011
NCI
$100,000
The Time Distribution Method for Measuring Clinically Valid Quality of Life States
1.56 cal mo
The broad objective is to improve the measurement of quality of life in the behavioral and health sciences by
developing a novel assessment method and demonstrating it’s feasibility in patients who have had
hematopoietic stem cell transplants. The new approach asks the patient to use a highly intuitive interface
(Visual Time Analog = VITA) to partition the day into mutual exclusive, clinically valid, states of quality of life.
PENDING
Moinpour, Carol M, PhD
NIH
Home-Based Exercise for Patients Beginning Hormonal
Treatment for Prostate Cancer
12/01/2008 – 11/30/2010
$146,586
The purpose of the proposed pilot study is to evaluate the feasibility of recruiting 24 men to a home-based
strength training and walking exercise program at the beginning of hormonal therapy for prostate cancer; a
second major purpose is to evaluate the men’s adherence to the exercise program. Men just beginning
PHS 398/2590 (Rev. 11/07)
Page _____
Other Support Format Page
Principal Investigator/Program Director (Last, first, middle):
hormonal therapy for prostate cancer will be recruited from two clinical sites; exercise training and weekly
phone follow-up will be done by Fred Hutchinson Cancer Research Center Exercise Research Center
instructors.
R21 CA131651 (Donaldson)
NIH/NCI
The Time Distribution Method for Measuring Clinically Valid
Quality of Life States
04/01/2009 – 03/31/2011
$100,000
The Objective of this application is to improve measurement of quality of life in the behavioral and health
sciences by developing a novel assessment method and demonstrating its feasibility in patients who have
had hematopoietic stem cell transplants.
OVERLAP
There is no scientific or budgetary overlap in the active grants listed above. If the pending application is
funded, appropriate adjustments will be made to Dr. Moinpour’s effort. At no time will her effort exceed 12
calendar months, or 100%.
PHS 398/2590 (Rev. 11/07)
Page _____
Other Support Format Page